HCP
STLN

Holt Capital Partners’s Starling Oncology STLN Stock Holding History

Holt Capital Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Hold
29,534
– – 0.02% 165
2026
Q1 		$90.7K Hold
29,534
– – 0.01% 153
2025
Q4 		$105K Buy
+29,534
New +$110K 0.01% 151

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Holt Capital Partners's STLN Position: Q2 2026 in Review

Holt Capital Partners held its Starling Oncology (STLN) position steady in Q2 2026 at 29,534 shares worth $160K. The position accounts for 0.02% of the portfolio, ranked #165.

Holt Capital Partners first reported a position in STLN in Q4 2025 and has held it in 3 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Holt Capital Partners held 29,534 shares of Starling Oncology worth $160K as of Q2 2026.
  • Holt Capital Partners left its Starling Oncology share count unchanged in Q2 2026.
  • Starling Oncology made up 0.02% of Holt Capital Partners's portfolio in Q2 2026, its #165 holding.
  • Holt Capital Partners first reported a position in Starling Oncology in Q4 2025 and has held it in 3 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Holt Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.